These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28404874)

  • 21. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
    Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
    Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
    Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
    Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
    Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
    Saito S; Kikuchi J; Koyama D; Sato S; Koyama H; Osada N; Kuroda Y; Akahane K; Inukai T; Umehara T; Furukawa Y
    Clin Cancer Res; 2019 Mar; 25(5):1601-1611. PubMed ID: 30518632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
    Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
    Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
    Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
    BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
    Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
    ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
    Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
    Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
    Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
    Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
    Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
    Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
    Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
    J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antitumor activity of histone deacetylase inhibitor suberic bishydroxamate on acute myeloid leukemia cell lines].
    Xu YH; Yang CM; Qian WB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):491-7. PubMed ID: 23086640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
    Yang CY; Lin CK; Tsao CH; Hsieh CC; Lin GJ; Ma KH; Shieh YS; Sytwu HK; Chen YW
    Oncotarget; 2017 May; 8(20):33756-33769. PubMed ID: 28422711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
    Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
    J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.